{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:35:46Z","timestamp":1790994946399,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>The use of cannabidiol (CBD) in childhood refractory seizures has become a common therapeutic approach for specific seizure disorders in human medicine. Similarly, there is an interest in using CBD, cannabidiolic acid (CBDA) or cannabinoid-rich hemp products in the treatment of idiopathic epilepsy in dogs. We aimed to examine a small cohort in a pilot investigation using a CBD and CBDA-rich hemp product for the treatment of refractory epileptic seizures in dogs. Fourteen dogs were examined in a 24-week randomized cross-over study being provided placebo or CBD\/CBDA-rich hemp extract treatment at 2 mg\/kg orally every 12 h for each 12-week arm of the study. Serum chemistry, complete blood counts, serum anti-seizure medication (ASM) concentrations and epileptic seizure frequency were followed over both arms of the cross-over trial. Results demonstrated that besides a mild increase in alkaline phosphatase, there were no alterations observed on routine bloodwork at 2, 6, and 12 weeks during either arm of the study. Epileptic seizure frequency decreased across the population from a mean of 8.0 \u00b1 4.8 during placebo treatment to 5.0 \u00b1 3.6 with CBD\/CBDA-rich hemp extract (<jats:italic>P<\/jats:italic> = 0.02). In addition, epileptic seizure event days over the 12 weeks of CBD\/CBDA-rich hemp treatment were 4.1 \u00b1 3.4, which was significantly different than during the 12 weeks of placebo treatment (5.8 \u00b1 3.1; <jats:italic>P<\/jats:italic> =0.02). The number of dogs with a 50% reduction in epileptic activity while on treatment were 6\/14, whereas 0\/14 had reductions of 50% or greater while on the placebo (<jats:italic>P<\/jats:italic> = 0.02). No differences were observed in serum zonisamide, phenobarbital or bromide concentrations while on the treatment across groups. Adverse events were minimal, but included somnolence (3\/14) and transient increases in ataxia (4\/14) during CBD\/CBDA-rich hemp extract treatment; this was not significantly different from placebo. This further indicates that providing CBD\/CBDA-rich hemp extract during refractory epilepsy (only partially responsive to ASM), in conjunction with other ASM appears safe. Based on this information, the use of 2 mg\/kg every 12 h of a CBD\/CBDA-rich hemp extract can have benefits in reducing the incidence of epileptic seizures, when used concurrently with other ASMs.<\/jats:p>","DOI":"10.3389\/fvets.2022.939966","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:25:36Z","timestamp":1659086736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs"],"prefix":"10.3389","volume":"9","author":[{"given":"Gabriel A.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Carrera-Justiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Wakshlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"B1","first-page":"437S","article-title":"The cannabinoids as potential antiepileptics","volume-title":"J Clin Pharmacol.","author":"Karler","year":"1981"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/bph.14165","article-title":"Species-specific susceptibility to cannabis-induced convulsions","volume":"176","author":"Whalley","year":"2019","journal-title":"Br J Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2460\/ajvr.21.08.0120","article-title":"Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs","volume":"83","author":"Doran","year":"2021","journal-title":"Am J Vet Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"106525","DOI":"10.1016\/j.eplepsyres.2020.106525","article-title":"Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures","volume":"169","author":"Goerl","year":"2021","journal-title":"Epilepsy Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108442","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fvets.2018.00165","article-title":"Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs","volume":"5","author":"Gamble","year":"2018","journal-title":"Front Vet Sci."},{"key":"B8","first-page":"178","article-title":"Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs","volume-title":"Can J Vet Res.","author":"Bartner","year":"2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fvets.2020.00505","article-title":"Pharmacokinetics of cannabidiol, cannabidiolic Acid, delta9-Tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract","volume":"7","author":"Wakshlag","year":"2020","journal-title":"Front Vet Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials","volume":"143","author":"Gunning","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2460\/javma.254.11.1301","article-title":"Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy","volume":"254","author":"McGrath","year":"2019","journal-title":"J Am Vet Med Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmarten","year":"2021","journal-title":"Seizure."},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14737175.2021.1834383","article-title":"Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome","volume":"21","author":"Lattanzi","year":"2021","journal-title":"Expert Rev Neurother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12917-015-0464-z","article-title":"International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals","volume":"11","author":"Bhatti","year":"2015","journal-title":"BMC Vet Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in Lennox-Gastaut Syndrome","volume":"378","author":"Dravinsky","year":"2018","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug resistant seizures in Dravet Syndrome","volume":"376","author":"Dravinsky","year":"2017","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidol in patients with seizures associated with Lennox-Gastaut syndrome (GWP-CARE4): a randomized double blind, placebo controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3390\/molecules25112638","volume":"25","author":"Formato","year":"2020","journal-title":"Molecules."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1021\/acs.jnatprod.9b00600","article-title":"Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet Syndrome","volume":"82","author":"Anderson","year":"2019","journal-title":"J Nat Prod."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsalraphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br J Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/bph.12043","article-title":"Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation","volume":"168","author":"Bolognini","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1111\/bph.14019","article-title":"Tetrahydrocannabinolic acid is a potent PPAR\u03b3 agonist with neuroprotective activity","volume":"174","author":"Nadal","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.phymed.2012.04.002","article-title":"Effects of cannabinoids \u03949-tetrahydrocannabinol, \u03949-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures","volume":"19","author":"Moldzio","year":"2012","journal-title":"Phytomedicine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3389\/fneur.2019.00716","article-title":"Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E Study","volume":"10","author":"Huntsman","year":"2019","journal-title":"Front Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich Cannabis extracts over purified CBD in treatment-resistant epilepsy: Observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1939-1676.2000.tb02231.x","article-title":"Effects of long-term phenobarbital treatment on the liver in dogs","volume":"14","author":"M\u00fcller","year":"2000","journal-title":"J Vet Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors and inducers of human drug metabolizing enzymes: a systemic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","article-title":"Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use","volume":"8","author":"Brown","year":"2019","journal-title":"J Clin Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/0091-3057(91)90358-9","article-title":"Comparative metabolism of cannabidiol in dog, rat and man","volume":"40","author":"Harvey","year":"1991","journal-title":"Pharmacol Biochem Behav."},{"key":"B32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0378-4347(91)80587-3","article-title":"Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry","volume":"562","author":"Harvey","year":"1991","journal-title":"Chromatogr."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.939966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:25:42Z","timestamp":1659086742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.939966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":32,"alternative-id":["10.3389\/fvets.2022.939966"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2022.939966","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"article-number":"939966"}}